Medisun Precision Medicine Ltd. Watch

EX-10.1

from 8-K 4 pages This Settlement Agreement (“Agreement”) Dated 9th Day of August, 2017 Is Made 本和解協議(“本協議”)於2017年8月9日 Between: 由以下雙方簽署: Whereas: 鑒於

12/34/56

EX-10.2

from 8-K 1 page Material contract

12/34/56

EX-10.1

from 8-K 9 pages Share Purchase Agreement

12/34/56

EX-10.1

from 8-K 6 pages Patent Assignment Agreement

12/34/56

EX-10.1

from 8-K 7 pages License Agreement

12/34/56

EX-10.1

from 8-K/A 12 pages License Agreement

12/34/56

EX-10.21

from 8-K 6 pages Sublicense Agreement

12/34/56

EX-10.21

from 8-K 6 pages Sublicense Agreement

12/34/56

EX-10.20

from 8-K 9 pages Employment Agreement

12/34/56

EX-10.20

from 8-K 11 pages Patent Assignment Agreement

12/34/56

EX-10.19

from 8-K 3 pages Agreement for the Rendering of Services

12/34/56

EX-10.18

from 8-K 3 pages License Termination Agreement

12/34/56

EX-10.17

from 8-K 19 pages Exclusive License Agreement

12/34/56

EX-10.1

from 8-K 44 pages Securities Purchase Agreement

12/34/56

EX-10.13

from 10-K 12 pages Consulting Agreement

12/34/56

EX-10.2

from 8-K 12 pages Accurexa Inc. Secured Convertible Promissory Note

12/34/56

EX-10.1

from 8-K 9 pages Accurexa Inc. Consulting Agreement

12/34/56

EX-10.1

from 8-K 37 pages Exclusive License Agreement Between the Regents of the University of California and Accurexa, Inc. for Microinjection Brain Catheter [Uc Case No. Sf2012-063]

12/34/56

EX-10.1

from 8-K 1 page August 21, 2013 To: University of Arkansas for Medical Sciences Office of Research and Sponsored Programs 4301 West Markham, #718-3 Little Rock, Ar 72205 USA Attn: Sr. Contracts Attorney Re: Termination of Second Performance Period From September 1, 2013 Through March 31, 2014 CC: James Suen, Vladimir Zharov /S/ George Yu George Yu President & CEO Cyto Wave Technologies Inc

12/34/56

EX-10.1

from 10-Q 4 pages Secured Convertible Note

12/34/56